Literature DB >> 27045420

"How is cognitive remediation training perceived by people with schizophrenia? A qualitative study examining personal experiences".

Natalia A Contreras1,2, Stuart Lee1,2, Eric J Tan1,3, David J Castle4, Susan L Rossell1,2,3,4.   

Abstract

BACKGROUND: Meta-analytical findings have shown Cognitive Remediation (CR) effectiveness in augmenting cognitive and functional outcomes. Comparatively, a minimum amount of qualitative evidence has been reported to date. AIMS: This study aimed to explore the subjective experience of participants undertaking a CR trial.
METHOD: Twenty people with schizophrenia completed a questionnaire-facilitated interview, after having completed 20 h of CR. Thematic analysis was then used to identify codes and themes.
RESULTS: Three themes were identified. In relation to reported benefits, all participants found the training to be a positive experience, with 70% having identified cognitive improvements, 45% improved motivation or confidence and 20% improved social skills. The role of the cognitive trainer in being supportive, adaptive and instructive was consistently reported as important, and most participants commented positively about the group format. Fewer participants had observed a transfer to real life settings, with improved social skills, use of cognitive strategies or aspects of everyday living reported by 40% of participants.
CONCLUSIONS: These data highlight that all participants reported participation in CR to be a positive experience, with many reporting observed benefits following participation. Key aspects of the training that contributed to this positive experience were also identified and may assist in the further development of this intervention.

Entities:  

Keywords:  Cognitive remediation; qualitative research; schizophrenia; subjective experience

Mesh:

Year:  2016        PMID: 27045420     DOI: 10.3109/09638237.2016.1167856

Source DB:  PubMed          Journal:  J Ment Health        ISSN: 0963-8237


  6 in total

1.  Evaluation of a computer-assisted cognitive remediation program for young people with psychosis: A pilot study.

Authors:  Andrew M H Siu; Rita S H Ng; Magdalene Y C Poon; Catherine S Y Chong; Clara M W Siu; Sally P K Lau
Journal:  Schizophr Res Cogn       Date:  2020-09-11

2.  How does awareness of cognitive impairment impact motivation and treatment outcomes during cognitive remediation for schizophrenia?

Authors:  Alice M Saperstein; David A Lynch; Min Qian; Alice Medalia
Journal:  Schizophr Res       Date:  2020-03-07       Impact factor: 4.939

3.  Effects of Cognitive Remediation on Cognition, Metacognition, and Social Cognition in Patients With Schizophrenia.

Authors:  Cristiana Montemagni; Elisa Del Favero; Cecilia Riccardi; Laura Canta; Mario Toye; Enrico Zanalda; Paola Rocca
Journal:  Front Psychiatry       Date:  2021-07-09       Impact factor: 4.157

4.  Feasibility and acceptability of remotely accessed cognitive remediation for schizophrenia in public health settings.

Authors:  Alice Medalia; Alice M Saperstein; Ana Stefancic; Shanique Meyler; Sarah Styke; Min Qian; Jun Liu; Leopoldo J Cabassa
Journal:  Psychiatry Res       Date:  2021-04-21       Impact factor: 11.225

Review 5.  Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research.

Authors:  Alexandre A Guerin; Yvonne Bonomo; Andrew John Lawrence; Bernhard Theodor Baune; Eric J Nestler; Susan L Rossell; Jee Hyun Kim
Journal:  Front Psychiatry       Date:  2019-12-17       Impact factor: 4.157

6.  The CIRCuiTS study (Implementation of cognitive remediation in early intervention services): protocol for a randomised controlled trial.

Authors:  Til Wykes; Eileen Joyce; Tjasa Velikonja; Andrew Watson; Gregory Aarons; Max Birchwood; Matteo Cella; Sue Dopson; David Fowler; Kathy Greenwood; Sonia Johnson; Paul McCrone; Jesus Perez; Andrew Pickles; Clare Reeder; Diana Rose; Swaran Singh; Dominic Stringer; Matthew Taylor; Rumina Taylor; Rachel Upthegrove
Journal:  Trials       Date:  2018-03-15       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.